Hodgkin lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:98293
Who is this for?
Show terms as
14Active trials24Specialists8Treatment centers1Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Dec 2025Prognostic Model of Elderly Hodgkin Lymphoma in China

Tianjin Medical University Cancer Institute and Hospital

TrialACTIVE NOT RECRUITING
Nov 2025European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

Assistance Publique - Hôpitaux de Paris

TrialRECRUITING
Aug 2025Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

University of Cologne — PHASE2

TrialNOT YET RECRUITING
Dec 2024BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Xiuhua Sun — PHASE4

TrialNOT YET RECRUITING
Dec 2024CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

New York Medical College — PHASE1, PHASE2

TrialNOT YET RECRUITING
Oct 2024Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

Sun Yat-sen University — PHASE2

TrialRECRUITING
Sep 2024Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Children's Cancer Group, China — PHASE2, PHASE3

TrialRECRUITING
May 2024Hodgkin's Disease and Chemotherapy Before 40 Years

Lille Catholic University — NA

TrialNOT YET RECRUITING
Mar 2024Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

University of Cologne — PHASE2

TrialRECRUITING
Mar 2024Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

University College, London — PHASE2

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Hodgkin lymphoma.

14 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

14 recruitingView all trials with filters →
Phase 31 trial
HD21 for Advanced Stages
Phase 3
Active
PI: Peter Borchmann, Prof. (University of Cologne, I. Dept. of Medicine) · Sites: Cologne · Age: 18–60 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 26 trials
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Phase 2
Active
PI: Helen Heslop, MD (Baylor College of Medicine) · Sites: Duarte, California; Chicago, Illinois +3 more · Age: 12–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
Phase 2
Actively Recruiting
· Sites: Guangzhou, Guangdong · Age: 1–18 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
Phase 2
Actively Recruiting
PI: Zhiming Li (Sun Yat-sen University) · Sites: Guangzhou, Guangdong · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2
Active
PI: Lapo Alinari, MD, PhD (Ohio State University Comprehensive Cancer Center) · Sites: Atlanta, Georgia; Columbus, Ohio · Age: 19–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2
Actively Recruiting
PI: Andreas Engert, Prof. (1st Department of Medicine, Cologne Universit Hosp) · Sites: Cologne · Age: 18–65 yrs
View on ClinicalTrials.gov ↗I'm interested →
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
Phase 2
Active
PI: Graham Collins (Oxford University Hospitals NHS Trust) · Sites: Truro, Cornwall; Norwich, Norfolk +8 more · Age: 16–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 11 trial
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Phase 1
Active
PI: Jonas Paludo, MD (Mayo Clinic in Rochester) · Sites: Rochester, Minnesota · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
N/A1 trial
Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin
N/A
Actively Recruiting
PI: Daniel Molin, MD, PhD (Uppsala University Hospital) · Sites: Gothenburg; Lund +4 more · Age: 18–60 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other4 trials
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
Actively Recruiting
PI: Mathieu SIMONIN, MD (Assistance Publique - Hôpitaux de Paris) · Sites: Paris
View on ClinicalTrials.gov ↗I'm interested →
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Actively Recruiting
PI: Luminari Stefano, MD (Azienda USL - IRCCS di Reggio Emilia) · Sites: Milan, MI; Reggio Emilia, RE +10 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Prognostic Model of Elderly Hodgkin Lymphoma in China
Active
· Sites: Tianjin, Tianjin Municipality · Age: 60–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Actively Recruiting
PI: Eric J Chow (Children's Oncology Group) · Sites: Birmingham, Alabama; Phoenix, Arizona +77 more
View on ClinicalTrials.gov ↗I'm interested →

Specialists

24 foundView all specialists →
WD
Won Seog Kim, Dr
Specialist
PI on 1 active trial
SD
Shuhua Yi, Dr
Specialist
PI on 1 active trial
AP
Andreas Engert, Prof.
Specialist
PI on 5 active trials
SM
Steven Horwitz, MD
Specialist
PI on 4 active trials
KM
Karenza Alexis, MD
BRONX, NY
Specialist
PI on 1 active trial
XM
Xinxin Cao, MD
Specialist
PI on 1 active trial
AM
Armando Santoro, MD
Specialist
PI on 19 active trials
CS
Craig Sauter
CLEVELAND, OH
Specialist
PI on 1 active trial1 Hodgkin lymphoma publication
MM
Massimo Federico, MD
FORT HOOD, TX
Specialist
PI on 7 active trials
KP
Kelly McConnell, PhD
Specialist
PI on 2 active trials
JP
James L. Rubenstein, MD, PhD
Specialist
PI on 2 active trials
AM
Alain H Rook, M.D.
PHILADELPHIA, PA
Specialist
PI on 1 active trial
LT
Lorenz Truemper
Specialist
PI on 1 active trial
CG
Christian Gisselbrecht
Specialist
PI on 1 active trial6 Hodgkin lymphoma publications
AM
Andrei M Iagaru, MD
STANFORD, CA
Specialist
PI on 1 active trial1 Hodgkin lymphoma publication
AM
Amanda F. Cashen, M.D.
SAINT LOUIS, MO
Specialist
PI on 1 active trial
BS
Brian Shaffer
Specialist
PI on 1 active trial
BP
Boris V Afanasyev, Ph.D
Specialist
PI on 2 active trials
DS
Delphine Senecal
Specialist
PI on 1 active trial
JM
John Martin
Specialist
PI on 1 active trial
RP
Ravi Pingali
Specialist
PI on 1 active trial
YN
Yago Nieto
HOUSTON, TX
Specialist
PI on 4 active trials
JN
J. Nuver
Specialist
PI on 1 active trial
KK
Kevin Krull
HOUSTON, TX
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

ADCETRIS

Seagen

Hodgkin Lymphoma

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Hodgkin lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hodgkin lymphomaForum →

No community posts yet. Be the first to share your experience with Hodgkin lymphoma.

Start the conversation →

Latest news about Hodgkin lymphoma

No recent news articles for Hodgkin lymphoma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hodgkin lymphoma

Are there clinical trials for Hodgkin lymphoma?

Yes — 14 recruiting clinical trials are currently listed for Hodgkin lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hodgkin lymphoma?

24 specialists and care centers treating Hodgkin lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Hodgkin lymphoma?

1 patient support program are currently tracked on UniteRare for Hodgkin lymphoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.